Europe Biodefense Market

The Europe Biodefense market is expected to reach US$ 1,286.58 Mn in 2027 from US$ 2,516.91 Mn in 2019. The market is estimated to grow with a CAGR of 8.8% from 2019-2027.

The growth of the Biodefense market is driven by factors such as the favorable government initiatives increase in the number of naturally occurring outbreaks, increasing threat of biological weapons and nuclear armed ICBM in the Europe region. However, fluctuations in funding due to changing EU is likely to restrain the market growth to a certain extent.

Biodefense is referred to the measures taken to restore biosecurity of a group of organisms that are, or may be, subject to biological threats or infectious diseases. It is an effective public health care system with strong disease surveillance and rapid actions designed to counter biological threats, to limit the spread of disease and provide surge medical care.

Disease outbreaks are usually caused by an infection, transmitted through person-to-person contact, animal-to-person contact, or from the environment or other media. Emerging infectious diseases are infections that have recently appeared within a population and are rapidly increasing or threaten to grow shortly. The World Health Organization warned in its 2007 report that infectious diseases are emerging at a rate that has not been seen before. Since the 1970s, about 40 infectious diseases have been discovered, including SARS, MERS, Ebola, chikungunya, avian flu, swine flu, zika, and most recently, coronavirus. In May through June 2011, a novel strain of Escherichia coli O104:H4 bacteria caused a significant outbreak of foodborne disease focused in northern Germany. In total, there were 3,950 people affected and 53 died, 51 of whom were from Germany. 800 people suffered from hemolytic uremic syndrome (HUS), which would lead to kidney failure. The growing prevalence of Ebola and Zika virus infections is also likely to contribute to the Biodefense market development. Due to coronavirus outbreak, As of 15 April, there have been 98,476 confirmed cases of COVID-19 in the UK, and 12,868 people with confirmed infection have died. Further, on March 18, 2020 Emergent BioSolutions signed development and manufacturing agreement with Vaxart for their experimental oral vaccine candidate for Coronavirus Disease.

The release of pathogenic agents such as anthrax or smallpox, biological toxins, chemical weapons such as nerve gas, or radioactive substances caused public threats in the past. In order to prevent such outbreaks, the government has planned various strategies. The growing prevalence of infectious diseases, such as coronavirus, Ebola and zika virus, is likely to boost the investments in the field of biodefense, thereby driving the Biodefense market growth.

Biological weapons (BWs) deliver toxins and microorganisms, such as viruses and bacteria, so as to intentionally inflict disease among people, animals, and agriculture. Biological attacks can result in destruction of crops, temporarily discomforting a small community, killing large numbers of people, or other outcomes. Biological weapons have a long history of use. In 1346, the invading Tartar army catapulted the bodies of plague victims into the Crimean Peninsula city of Kaffa and infected its citizens. In 1763, British troops under General Jeffrey Amherst gave the Delaware Indians blankets used by people with smallpox, possibly infecting the susceptible native population. Although recent advances in biotechnology have made it easier to develop dangerous viruses, bacteria, and toxins with fewer resources. This has increased concerns that individuals and groups could resort to bioterrorism to attack a population.

Moreover, due to factors such as increasing border threats, rising national security concerns, and changing dynamics of warfare, countries such as Russia, UK in Western Europe are inclined towards enhancing their missile weapon store. They are also modernizing their old missiles with the new propulsion system and warheads. Hence, as the threat for biological weapon and nuclear armed ICBM is increasing, governments of various countries are actively funding for biodefense, thereby, positively propelling the European market.

Rest of Europe Biodefense market Revenue and Forecasts to 2027 (US$ Bn)

Europe Biodefense Strategic Insights

Strategic insights for the Europe Biodefense provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Europe Biodefense Report Scope

Europe Biodefense Regional Insights

The geographic scope of the Europe Biodefense refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

EUROPE BIODEFENSE MARKET – MARKET SEGMENTATION

Europe Biodefense Market – By Product

• Anthrax
• Small pox
• Botulism
• Radiation/Nuclear
• Others

Europe Biodefense Market – By Country

• United Kingdom
• Germany
• France
• Spain
• Italy

Companies Mentioned

• Bavarian Nordic
• Alnylam Pharmaceuticals, Inc.
• SIGA Technologies
• Emergent BioSolutions Inc.
• Cleveland Bio Labs
• Dynavax Technologies
• Elusys Therapeutics, Inc.
• Soligenix
• Altimmune
• Pluristem Therapeutics